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Available online 21 March 2018TheWorld Health Organization has recently introducedmolecular prognostic-diagnostic biomarkers in the clas-
siﬁcation of Central Nervous System (CNS) tumors. In order to characterize subclasses of tumors that cannot ﬁnd
a precise location in the current classiﬁcation, and, or cannot be tested because of scantmaterial, it is important to
ﬁnd new molecular biomarkers in tissue and, or biological ﬂuid samples. In this study, we identiﬁed serum
microRNAs that could serve as biomarkers for the diagnosis and prognosis of patients with tumors of glial origin.
We retrospectively analyzed microRNA expression in the serum extracellular vesicles of patients with tumors of
glial origin. Extracellular vesicles RNA was analyzed by Nanostring. qRT-PCR conﬁrmed 6 overexpressed
microRNAs: hsa-miR-4443, hsa-miR-422a, hsa-miR-494-3p, hsa-miR-502-5p, hsa-miR-520f-3p, and hsa-miR-
549a. Hsa-miR-4443was the onlymicroRNA that showed signiﬁcant differences inmost comparisons. In situ hy-
bridization (ISH), conﬁrmed that our signature was mostly expressed in cancer cells.
Importantly, hsa-miR-549a and hsa-miR-502-5p expression predicted prognosis in patients with tumors of glial
origin. Althoughmore studies are needed,we demonstrated that serumvesiclesmicroRNAproﬁles are promising
diagnostic and prognosticmolecular biomarkers that will ﬁnd an actual application in the clinical practice of CNS
tumors.ir in Hum
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In 2016, the World Health Organization (WHO) published a new
classiﬁcation for Central Nervous System (CNS) tumors that, beside
deleting and adding histological subgroups, introduced, for the ﬁrst
time, molecular biomarkers that deﬁne new prognostic groups
(Louis et al., 2016). In attempt to merge the different clinical infor-
mation contributed by previous classiﬁcations, the International So-
ciety of Neuropathology (ISN) proposed a “layered” diagnostic path,
that includes the histologic classiﬁcation (layer 2), WHO grading
(layer 3), molecular information (layer 4) and an “integrated diagno-
sis” (layer 1) (Louis et al., 2014).However, because of their extensivean Cancer Genetics,
University, Columbus,
mbus, OH, USA.
c.edu. (C. CM).
n open access article underbiological variability some gliomas cannot be molecularly classiﬁed
(Masui et al., 2016). Furthermore, a group of glial tumors has not
yet found a precise molecular classiﬁcation: the “Not Otherwise
Speciﬁed” (NOS) cases include those tumors for which testing can-
not be performed due to limited tissue availability, low number of
neoplastic cells, or other causes (Louis et al., 2016). Clearly, patients
with a non-classiﬁed biological variant of gliomas and/or a “NOS”,
will not be able to beneﬁt of the molecularly targeted treatment.
On the other hand, imaging studies cannot microscopically deﬁne
clear margin in malignant lesions before and after surgery. Medica-
tions affecting Blood Brain Barrier (BBB) permeability, can produce
images with falsely reduced tumor burden (“pseudo-response”)
(Holdhoff et al., 2013). Treatment of high grade gliomas with radia-
tion and temodar can lead to “pseudo-progression”, causing unnec-
essary surgery or chemotherapy termination (Santangelo et al.,
2017). It is extremely important to ﬁnd molecular biomarkers aiding
in the diagnosis and classiﬁcation of these tumors on tissue samples
and, more importantly, on biological ﬂuids. MicroRNAs are non-the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2015; Peterson et al., 2015; Skog et al., 2008; Van Deun and
Hendrix, 2017) in length that modulate gene expression by regulat-
ing mRNA translation/degradation, playing key roles in physiologic
and pathologic processes, including cancer (Drusco and Croce,
2017). Moreover, microRNA proﬁles can classify human cancer, ren-
dering these small molecules suitable biomarkers to classify cancers
for diagnostic, prognostic and therapeutic purposes (Lu et al., 2005).
MicroRNAs are expressed in all tissues and biological ﬂuids (Drusco
et al., 2015; Mitchell et al., 2008; Russo et al., 2017), where they
are released either freely as chemically modiﬁed molecules, or asso-
ciated with proteins, or within extracellular vesicles (EVs) (Raposo
and Stoorvogel, 2013). Secreted by all type of cells, including cancer
cells, EVs are a system of intercellular communication throughwhich
proteins and nucleic acids are packed within small membrane spher-
ules and shipped at distant sites (Taylor and Gercel-Taylor, 2008).
Thus, microRNA proﬁling in EVs of patients' biological ﬂuid, may
lead to the identiﬁcation of new diagnostic and prognostic bio-
markers. In this study, we identiﬁed a microRNA signature of
serum EVs of patients with tumors of glial origin that was not only
able to differentiate between glioma and normal patients, but also
to predict survival.
2. Materials and Methods
2.1. Samples
Serum samples from 9 patients with Oligodendroglioma, 9 patients
with Astrocytoma and 10 patients with Glioblastoma were providedFig. 1. In situ hybridization histograms. ISHwas performed on 12 Normal CTRL (perilesional gre
The intensity of expression of eachmicroRNA of the signaturewas scored in each group of Gliomby UCSF neurosurgery department (Genomic Shared Resources Core is
NIH subsidized Shared Resources CCSG:P30CA016058), while 8 normal
controls were provided by Ohio State University, Columbus, OH (Proto-
col: 2005C0014) (Fig. 1). In situ hybridization FFPE sections of 12
oligodendrogliomas, 10 astrocytomas, 13 glioblastoma samples and 12
non-neoplastic perilesional grey matter specimens were provided by
the Regina Elena Institute, Dept. of Pathology, Rome (Protocol: 825/
16).Collection of tissue and serum samples has been conducted accord-
ing to the standards established by the Declaration of Helsinki, and in-
formed consent was obtained according to the approved protocols
mentioned above.2.2. Extracellular Vesicles RNA Extraction
In order to avoid any cellular contamination samples were centri-
fuged 3 times at 3500 rpm for 20 min. After each centrifugation, super-
natant was transferred to a new tube. Extracellular vesicles were
extracted from 250μl of serum using Exoquick plus (System Bioscience
cat#EXOQ5TM-1) and following manufacturer's instructions. The
exosomal pellet was resuspended in 1.5 ml of TRIReagent (SIGMA-AL-
DRICH cat#T9424-200 ml), and 2 μl of 33.3 attoMole solution of spike-
ins (cel-miR-248 and ath-miR159a) were added to each sample. The
RNAwas then extracted using the NORGEN RNA Clean-up and Concen-
tration kit (cat#23600) and RNA was isolated following manufacturer's
instructions.Furthermore, samples were concentrated and cleaned up
from any chemical residues by centrifugation through Amicon ultra
0·5 centrifuge ﬁlters (SIGMA ALDRICH cat#Z740169-96EA), and then
speed-vacued to 10 μl of volume.ymatter), 12 Grade II oligodendrogliomas, 10 Grade II astrocytomas and 13 glioblastomas.
awith numbers going from 0, in case of absent expression, to 3+ formaximal expression.
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A total of 36 samples were processed with NanoString nCounter
Human v3 miRNA Expression Assay. A 3 μl volume of RNA suspension
was used as input for nCountermiRNA sample preparation reactions ac-
cording to manufacturer's instructions (NanoStringTechnologies). In
this study, we used a volumetric approach rather than ﬁxed concentra-
tions. Extracted RNA was concentrated to a ﬁnal volume of 10 μl: 3 μl
were used for the NanoString array, and 7 μl were diluted 1:7 for RT-
PCR validation. NanoString allows to concurrently measure 800 differ-
ent microRNAs in each sample. Three μl of RNA suspension were
annealedwithmultiplexed DNA tags (miR-tag) and target speciﬁc brid-
ges. Mature microRNAs were bound to speciﬁc miR-tags using a Ligase
enzyme. Tags in excess were removed by an enzyme clean-up step.
The taggedmicroRNAs productwas diluted 1:5. Twentymicrolitre of re-
ported probes in hybridization buffer and 5 μl of Capture probes, were
combined with 5μl of the tagged microRNAs diluted solution. The over-
night hybridization (16 to 20 h) at 65 °C allowed to complex sequence
speciﬁc probes with targets. Probes' excess was removed using two-
step magnetic beads based puriﬁcation on an automated ﬂuidic han-
dling system (nCounter Prep Station), and target/probe complexes
were immobilized on the cartridge for data collection. Data collection
was carried out on the nCounter Digital Analyzer (NanoString Technol-
ogies) following the manufacturer's instructions, to count individual
ﬂuorescent barcodes and quantify target RNA molecules present in
each sample. For each assay, a high-density scan (600 ﬁelds of view)
was performed. NanoString raw data was analyzed with nSolver™, a
software provided by NanoString Technologies. Negatives were used
to perform background subtraction. Positives were used to perform
technical normalization to adjust any lane by lane variability due to dif-
ferences in hybridization, puriﬁcation or binding. Data analysis was car-
ried out using the software provided by NanoString technologies. Data
was normalized by calculating the geometric mean of the top 100
miRNAs in all samples, as recommended by NanoString. P-values were
calculated using the LIMMA package (Linear Models for Microarray
Data) from the Bioconductor R project. The p-values were adjusted for
multiple testing using the Benjamini and Hochberg method to control
the False Discovery Rate (FDR) (Drusco et al., 2015). Raw data are avail-
able at NCBI GEO: GSE112462.
2.4. Taqman Stem-Loop miRNA RT-qPCR
Expression ofmature singlemiRNAswas assessed in triplicate by the
TaqMan Stem-loop miRNAassay (Applied Biosystems, Foster City, CA,
USA), and normalized to Cel-miR-248 (Applied Biosystems) in all 36
samples. In this study we used a volumetric approach rather than
ﬁxed concentrations. Extracted RNAwas concentrated to a ﬁnal volume
of 10 μl: 3 of them were used for the NanoString array, while the re-
maining 7 μl were diluted 1:7. Reverse transcription was carried out
with 1.3 μl of the 1:7 diluted RNA stock. P-Values were calculated by
one-tailed t-test. RT-qPCR box plots are represented on Fig. 3 as
2∧−ΔCt relative expression to Cel-miR-248. Means ± standard error of
the mean (s.e.m.), *P b 0.05, by two-tailed Student's t-test (Drusco
et al., 2015).
2.5. In Situ Hybridization(ISH)
FFPE sections (Regina Elena Institute, Rome) of primary central ner-
vous system tumors (12 oligodendrogliomas grade II, 10 astrocytomas
grade II, 13 glioblastoma multiforme samples) and 12 non-neoplastic
perilesional grey matter specimens were stained for the 6 selected
miRs. All probes were labeled with 5′-digoxigenin and synthesized by
Exiqon (Denmark). In situ hybridization was performed as described,
with minor modiﬁcations (Drusco et al., 2015). Negative controls in-
cluded omission of the probe and the use of a scrambled LNA probe;U6 was used as positive control (Exiqon). Slides were counterstained
in fast red solution.
2.6. Survival Data Analysis
ISH tissue samples' clinical data were not available. Overall Survival
(OS) curvesweremade analyzing only the clinical data of serum sample
patients by using the Kaplan-Meier method. Censoring occurred at the
date of the last follow-up or at the date of the death due to any cause.
The log-rank test was performed for each comparison between sub-
groups. OS curves and log-rank test were generated by using ggsurvplot
function from survminer R package.
3. Results
This article is the result of a pilot study aimed to ﬁndnew serumbio-
markers in patients with CNS tumors of glial origin.We focused on ﬁnd-
ing a microRNA signature in serum EVs that could differentiate among
these tumors and normal controls. All patients' sera were collected at
the time of surgery (Table 1). EVs were extracted from the serum of 9
patients diagnosed with Grade II oligodendroglioma, 9 patients with
Grade II astrocytoma, 10 patients with glioblastoma and 8 healthy do-
nors as controls. Patients were arranged into four groups: Normal con-
trols (CTRL), oligodendroglioma (Oligo), astrocyoma (Astro) and
glioblastoma (GBM). Samples were processed with the NanoString
nCounter Human v3 Expression Assay.In order to reach our goal we cre-
ated 7 groups: CTRL, GBM, Astro, Oligo, Low grade tumors (Astro and
Oligo), High grade tumors (GBM), and Tumors (Astro, Oligo and
GBM). We ﬁrst performed nine comparisons: we compared each of
the original 4 patients groups against each other (6 comparisons),
CTRL against either High grade tumors or Low grade tumors, High
grade tumors against Low grade tumors, and Glial tumors against
CTRL (Table 2). Since GBM is the only high grade tumor type of our
study, the comparisons CTRL versus GBM, and CTRL versus High grade
tumors were considered as one. For each comparison, we then selected
signiﬁcantly differentially expressed microRNAs that showed N35
counts in one of the two compared groups. We ﬁnally identiﬁed
microRNAs that were expressed in more than one group and those
that were expressed only in one group. Candidate microRNAs were
then selected based on the average number of counts and standard de-
viation.We also selected fewmicroRNAs that, althoughnot ﬁtting in our
selection method, showed interesting count patterns in the initial com-
parisons but, only one (hsa-miR-502-5p) was conﬁrmed by RT-qPCR.
Out of ﬁfteen microRNAs tested, 6 were validated by RT-qPCR: hsa-
miR-4443, hsa-miR-422a, hsa-miR-494-3p, hsa-miR-502-5p, hsa-miR-
520f-3p, and hsa-miR-549a were signiﬁcantly differentially expressed
among groups, and were all up-regulated (Table 2 & Table2S). Only
two microRNA were found signiﬁcantly down-regulated at NanoString
(hsa-miR-144-3p, hsa-miR-19a-3p), but none of them was validated
by RT-qPCR. This ﬁnding might be due to overly low amounts of
down-regulated microRNA in biological ﬂuids. On the other hand, we
are comparing two distinct techniques with different sensitivity: one
counts singlemolecules, while the other ampliﬁes an imprecise number
of molecules (Bumgarner et al., 2008). Table2 shows the different com-
parisons with the corresponding p-Values when signiﬁcant differences
were observed with either or both techniques for each microRNA of
our signature (fold changes are reported in Table 2S). Both techniques
showed signiﬁcant differences in the following comparisons: CTRL vs
Astro for hsa-miR-4443, CTRL vs GBM for hsa-miR-520f-3p and -549a,
GBM vs Oligo for hsa-miR-422a, -494-3p and -502-5p, CTRL vs Low
Grade for hsa-miR-4443, and in Tumors vs CTRL for hsa-miR-549a and
-4443. Signiﬁcant differences were found only at NanoString between
CTRL and Oligo for has-miR-494-3p, -520f-3p, and -549a, between
CTRL and Astro for hsa-miR-494-3p, -520f and -549a, between GBM
and Astro for hsa-miR-422a, -494-3p and -4443, between CTRL and
Low Grade tumors for hsa-miR-494-3p, -520f-3p, and -549a, between
108 D. A et al. / EBioMedicine 30 (2018) 105–112Low and High Grade for hsa-miR-422a, -494-3p and a borderline differ-
ence for hsa-miR-502-5p, and between Tumors and CTRL for hsa-miR
-520f-3p.Since RT-qPCR and in situ hybridization (ISH) are commonly
applied technologies in the clinical ﬁeld for the detection of molecular
diagnostic markers, we considered RT-qPCR results as reference. ISH
further conﬁrmed our ﬁndings and provided information on the locali-
zation, type of cell producing the tested microRNA and, as for most ISH
diagnostic and prognostic biologicalmarkers, its quantitative evaluation
(Figs. 1 & 2).We performed RT-qPCR on total RNA of serum EVs, and ISH
on tissue samples coming from a different set of patients with tumors of
glial origin for every identiﬁed microRNA. At RT-qPCR, every single
microRNA of our signature was able to signiﬁcantly differentiate be-
tween CTRL and GBM (Table2 & Fig. 3), while none was able to distin-
guish between CTRL and Oligo, GBM and Astro, and Low versus High
grade (Table 2 & Fig. 3). ISH histograms representing the different de-
gree of expression of each microRNA tested on tissue samples are
shown in Fig. 1. Themost representative ISH images of each group of tu-
mors for every microRNA of our signature are displayed in Fig. 2. Tissue
staining showed that every probe was able to differentiate CTRL from
GBM.With the exception of miR-4443, that was able to differentiate be-
tween CTRL andOligo, allmicroRNAs showedoverlapping coloration in-
tensities in the two groups. Only miR-4443 was signiﬁcantly up-
regulated in Astro compared to CTRL at RT-qPCR and NanoString
(Table 2 & Fig. 3). At ISH, Astrocytomas were staining darker than
CTRL in most of the cases. With the exception of miR-549a, all the re-
mainingmicroRNAs tested by RT-qPCRwere able to signiﬁcantly differ-
entiate between GBM and Oligo (Table 2 & Fig. 3). As shown in Fig. 1,
tissue staining strongly conﬁrmed this ﬁnding for miR-422a and miR-
4443, while miR-494-3p, -502-5p and -520f-3p expressions levels be-
tween the two groups were overlapping. Although with borderline p-Table 1
Glial tumor patients' clinical and molecular data. In the table are reported the age and gender o
prognosis at the time of the last follow-up, and the molecular ﬁndings. Empty boxes correspon
Patients' clinical & molecular data
Oligodendroglioma (WHO gr2) Age Sex Time to follow up Status
1 57 M 2225 DEAD
2 47 M 4697 ALIVE
3 39 F 4725 ALIVE
4 31 M 3907 ALIVE
5 47 F 3182 ALIVE
6 39 F 3354 ALIVE
7 48 F 3001 ALIVE
8 62 F 1687 DEAD
9 74 M 1242 DEAD
Astrocytoma
(WHO gr2)
Age Sex Time to follow up Status
1 48 F 537 DEAD
2 33 M 2216 DEAD
3 29 F 4109 ALIVE
4 34 M 4565 DEAD
5 31 F 4151 ALIVE
6 46 M 3133 ALIVE
7 42 F 3211 ALIVE
8 47 M 2285 ALIVE
9 48 F 2250 ALIVE
GBM
(WHO gr4)
Age Sex Time to follow up Status
1 37 M 3076 ALIVE
2 57 M 537 DEAD
3 59 M 212 DEAD
4 59 F 2297 DEAD
5 57 M 4 DEAD
6 63 F 247 DEAD
7 77 M 136 DEAD
8 65 M 386 DEAD
9 43 F 247 DEAD
10 46 M 392 DEADValues, RT-qPCR showed that miR-4443 was able to distinguish be-
tween Oligo and Astro and between Low Grade tumors and CTRLs
(Table 2). The latter comparison was also signiﬁcant at NanoString
with a p-value = 0.003, suggesting that this difference could become
more reliable using a larger number of samples. Fig. 1 shows that miR-
4443 and miR549a tissue expression gradually increased throughout
the four groups. A similar pattern of expression was observed with all
the microRNAs of our signature with the exception of miR-520f-3p,
which instead showed the higher variability of expression in
Astrocytomas.
Only miR-4443 and miR-549a were signiﬁcantly differentiating be-
tween Glial Tumors and CTRL at both RT-qPCR and NanoString. ISH
staining showed stronger differences ofmiR-4443 expression in glial tu-
mors compared to control, but conﬁrmed miR-549 ability of differenti-
ating between Glial Tumors and CTRL in half of the cases. Although
ISHwas conﬁrmatory of RT-qPCR results, our aimwas to ﬁnd diagnostic
microRNAs in serum vesicles of patients with glial tumors. ISH role was
to understand what type of cells was actually producing the tested
microRNA, and to identify those microRNA that could lead us to new
therapeutic targets. Fig. 3 boxplots represent RT-qPCR signiﬁcant ﬁnd-
ings for eachmicroRNA of our signature: all of themwere able to differ-
entiate between a Glioblastoma and a Normal patient, but only miR-
549a and miR-4443 were able to distinguish between the serum of pa-
tients with Glial Tumors and Normal healthy patients.We built survival
curves to investigate if any of thosemicroRNAs could be of any prognos-
tic signiﬁcance. Survival rateswere evaluated as days from the diagnosis
to the last follow-up. Using the median as threshold, we observed that
higher levels of expression of miR-549a (p value = 0.022) and miR-
502-5p (p value = 0.021) were signiﬁcantly associated with a
prolonged survival of patients with Oligodendroglioma andf each patient, the number of days from the diagnosis to the time of the last follow up, the
d to those cases in which the biomarker was not tested.
IDH 1 ATRX 1p19q Integrated diagnosis
1 1 Astrocytoma,IDH mutant
1 0 Oligodendroglioma,IDH mutant, NOS
1 0 1 Oligodendroglioma,IDH mutant, 1p19q codeleted
1 1 Oligodendroglioma,IDH mutant, NOS
1 1 Astrocytoma,IDH mutant
1 1 Oligodendroglioma,IDH mutant, 1p19q codeleted
1 1 Oligodendroglioma,IDH mutant, 1p19q codeleted
1 1 Oligodendroglioma,IDH mutant, 1p19q codeleted
1 1 Oligodendroglioma,IDH mutant, 1p19q codeleted
IDH 1 ATRX 1p19q Integrated diagnosis
0 0 Astrocytoma, NOT IDH mutant R132H
NA NA Astrocytoma, NOS
0 0 Astrocytoma, NOT IDH mutant R132H
1 1 Astrocytoma, IDH mutant
1 0 Astrocytoma, IDH mutant,NOS
1 1 Oligodendroglioma, IDH mutant, 1p/19q codeleted
1 1 Oligodendroglioma, IDH mutant, 1p/19q codeleted
1 1 Astrocytoma, IDH mutant
0 0 Astrocytoma, NOT IDH mutant R132H
IDH 1 ATRX 1p19q Integrated diagnosis
1 1 GBM, IDH mutant
0 GBM, NOT IDH mutant R132H
0 GBM, NOT IDH mutant R132H
0 GBM, NOT IDH mutant R132H
0 GBM, NOT IDH mutant R132H
0 GBM, NOT IDH mutant R132H
0 GBM, NOT IDH mutant R132H
0 GBM, NOT IDH mutant R132H
0 GBM, NOT IDH mutant R132H
0 GBM, NOT IDH mutant R132H
Table 2
Nanostring and RT-qPCR signiﬁcant comparisons. RT = RT-PCR, NS = NanoString Assay, n.s. = Not Signiﬁcant. Nanostring and RT-PCR signiﬁcant pValues are showed for each tested
microRNA and comparison. P-Values are written in bold for those microRNAs that showed a signiﬁcant differential expression in the corresponding comparison. Bold boxes frame those
p-Values that were found signiﬁcant with both technologies (RT & NS). All microRNAs were found up-regulated in signiﬁcant comparisons. Comparison boxes that did not show any sig-
niﬁcant difference with both techniques were left empty.
Nanostring and RT-qPCR Signiﬁcant comparisons
p-Values
miR-422a miR-494-3p miR-502-5p miR-520f miR-549a miR-4443
Comparisons RT NS RT NS RT NS RT NS RT NS RT NS
CTRL vs OLIGO n.s. 0.017 n.s. 0.014 n.s. 0.007
CTRL vs ASTRO n.s. 0.022 n.s. 0.001 n.s. 0.001 0.045 0.0006
CTRL vs GBM 0.005 n.s. 0.001 n.s. 0.045 n.s. 0.012 0.001 0.040 0.042 0.032 n.s.
GBM vs OLIGO 0.006 0.016 0.001 0.038 0.040 0.046 0.017 0.033 n.s.
GBM vs ASTRO n.s. 0.010 n.s. 0.048 n.s. 0.020
OLIGO vs ASTRO 0.048 n.s.
CTRL vs LOW GRADE n.s. 0.008 n.s. 0.001 n.s. 0.001 0.049 0.003
LOW vs HIGH GRADE n.s. 0.004 n.s. 0.018 n.s. 0.049
TUMORS vs CTRL n.s. 0.0004 0.017 0.002 0.005 0.012
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threshold, miR-502-5p overexpression was linked to increased mortal-
ity in patients with Astrocytoma (Fig. 4). Only one young patient with
low expression of miR-502-5p died after N4000 days from diagnosis.
We did not have enough information and, or follow-up serum samples
to explain this event.MiR-502-5p expression levelsmight have changed
during the course of the disease. ISH patients' clinical information were
not available to validate serum EVs patients' data. More studies with
follow-up samples are needed in order to strengthen these ﬁndings.
4. Discussion
The molecular characterization of tumors has become an essential
diagnostic step for the management of several cancers. As a result, theFig. 2. Representative in situ hybridization images. In Situ Hybridization images of the most
signature. Normal perilesional tissue pictures of every tested microRNA are instead in singletoconcept of personalized therapy has entered in the clinical oncologic
practice, where teams of physicians are focused in targeting mutations
and treat the speciﬁc tumor, rather than addressing a generic disease.
Moreover, the discovery of microRNAs has disclosed the complex net-
work of pathways regulating cellular physiologic and pathologic pro-
cesses, and has given new hopes for the classiﬁcation and the
diagnostic and prognostic evaluation of cancer patients. Glioblastoma
tissue signatures have shown to differentiate glioblastoma subclasses
and have been connected to signaling pathways involved in cell growth
(Kim et al., 2011). MicroRNAs have been found in all kind of biological
ﬂuids, including serum and plasma, where they freely circulate, or
within extracellular vesicles. Within the CNS, extracellular vesicles are
released by neurons, oligodendroglial cell, and microglia (Fauré et al.,
2006; Krämer-Albers et al., 2007; Lachenal et al., 2011), and by tumortwo representative tissue sections in different type of Gliomas for each microRNA of the
n.
Fig. 3.RT-PCRboxplots of signiﬁcant comparisons. The comparison is represented by the line at the top of the boxplotwhere eachend of the line indicates one groupof the comparison. The
stars specify the pValue: ** for a p-value b 0.01, * for a p-value b 0.05.
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monprimary tumor of the CNS, representing the 31%of all brain tumors,
and the 81% of brain malignant tumors (Ostrom et al., 2015). The het-
erogeneity of gliomas accounts for their different prognostic behavior
that can't be always predicted by current biomarkers. In an effort to
ﬁnd new molecular biomarkers, we proﬁled microRNAs in the serum
extracellular vesicles of patients with tumor of glial origin. Extracellular
vesicles were extracted from serum with the Exoquick polymeric pre-
cipitation (Peterson et al., 2015) which according to Van Deun et al.
leads to a concomitant isolation of non-exosomal AGO2-bound
microRNAs (Van Deun and Hendrix, 2017). Instead Li et al. showed
that AGO2-microRNAs complexes are also present in extracellular vesi-
cles (Li et al., 2012). Clearly, the extracellular vesicles topic will remain
opened until the scientiﬁc community has deﬁnitive ﬁndings and stan-
dardized sorting methods. The signature included 6 up-regulated
microRNAs: miR-422a, -494-3p, -4443, -502-5p, -520f-3p, and -549a.
All microRNAs signiﬁcantly differentiated between GBM and Normal
controls, but only miR-4443 was able to differentiate Astrocytomas
from controls and Oligodendrogliomas. MicroRNA-4443 and -549a
could distinguish between tumors of glial origin and normal controls.
Interestingly, down-regulation of miR-549a was also associated with
poor survival in patients with Oligodendrogliomas (Fig. 4 p value =
0.022). All Oligodendroglioma patients were carrying IDH mutation, 5
had an associated 1p/19q codeletion, and 2 were NOS. None of these
molecular markers could be connected with the prognosis. Patients
with miR-549a up-regulation were not living N2225 days from diagno-
sis. While miR-4443 seems to induce epirubicin resistance in breast tu-
mors (Chen et al., 2016), there is no reported involvement of miR-549a
in cancer. ISHdemonstrated that our signaturewasmainly expressed by
cancer cells, and showed, with the exception of miR-520f-3p, that at
different degrees of intensity, the expression of all probes was gradually
increasing from controls to Oligodendrogliomas, from the latter to
Astrocytomas, reaching the highest staining in Glioblastomas. Com-
pared to the other groups, miR-520f-3p wasmostly expressed in Astro-
cytomas showing the two highest levels of expression. ThismicroRNA isdown-regulated in Glioblastomamicrovascular proliferation (Xu and Li,
2016). Theproneural subtype of Gliablastoma is characterized bymicro-
vascular proliferation (Barciszewska, 2016) and, thus, responds to
antiangiogenic drugs. We found that patients with high serum vesicles
levels of miR-520f-3p showed an almost signiﬁcant (p value = 0.089)
increase in survival compared to those in which the microRNA was
down-regulated (Fig. 1S). It is possible that different levels of expression
ofmiR-520f-3pmight differentiate among different Astrocytomas prog-
nostic and, or therapeutic groups: those that won't, and those that will
inevitably progress to Glioblastoma, those that will respond and those
that will not respond to antiangiogenic therapy. Compared to the
other groups, serum extracellular vesicle microRNA expression showed
thehighest variability in Astrocytoma. Overall, Astrocytomapatients be-
haved more similarly to Glioblastoma patients rather than Controls.
There was no signiﬁcant differential expression when comparing the
Astrocytoma against the Glioblastoma group, but, although with bor-
derline pValue (p value = 0.045), miR-4443 could signiﬁcantly distin-
guish between Astrocytoma and Controls. Oligodendroglioma
extracellular vesicles samples behavior was mostly similar to Normal
controls. MiR-422a, -494-3p, and 502-5p were differentiating Controls
and Oligodendrogliomas fromGlioblastoma patients. In the comparison
CTRL vs OLIGO by RT-qPCR, we could not validate any microRNA that
showed signiﬁcant differences at Nanostring. MicroRNA-422a sup-
presses cell proliferation, migration and invasion in Gliomas through
targeting of insulin-like growth factor1 (IGF1) (Wang et al., 2017a),
and its loss is associated with carcinogenesis in Glioblastoma (Liang
et al., 2016). In our survival study, down-regulation ofmiR-422a in Glio-
blastoma patient was almost signiﬁcantly associated with patients with
a poor prognosis (Fig. 1S p value = 0.09). MiR-494-3p inhibits invasion
and proliferationwhile promoting apoptosis in glioma cell lines through
PTEN/AKT pathway (Li et al., 2015), and it is also associated with the
progression from Glioma grade III to grade IV (Barciszewska, 2016). In-
terestingly, miR-502-5p could predict survival in Astrocytoma and Glio-
blastoma patients. Down-regulation of the microRNA was associated
with a favorable prognosis in Astrocytoma (p value = 0.027) with an
Fig. 4. Survival curves. Kaplan-Meier Survival curves for hsa-miR-549a and hsa-miR-502-5p expressed in serum extracellular vesicles of patients with Oligodendroglioma and,
Astrocytoma and Glioblastoma respectively. The red line indicates the overexpression, while the blue line the down-regulation of the tested microRNA.
111D. A et al. / EBioMedicine 30 (2018) 105–112expectancy of more of 4000 days of survival (Fig. 4). Only one patient
with low levels of miR-502-5p and an IDH mutant phenotype died at
4565 days from diagnosis, while patients with high expression did not
survive more that 2216 days from the diagnosis. Due to the lack of
follow-up samples we could not verify the level of expression of miR-
502-5p at the time of death. The samples of this study were collected
at the time of diagnosis (time 0). Conversely, in Glioblastoma patients
miR-502-5p overexpression was associated with a longer survival
(Fig. 4 p value = 0.021). Patients with low levels of the microRNA
were not surviving N537 days, while two patients with high expression
of miR-502-5p survived N2000 days. One patient was IDH negative and
the one with longer survival was instead an IDH mutant phenotype.
There are no literature reports of an involvement of miR-502-5p in
CNS tumors, but it has been found up-regulated in the serumof patients
with subarachnoid hemorrhage (SAH) (Lai et al., 2017). Other Authors
have conducted studies on serum, plasma, and whole blood samples
of Glioblastoma or Low-grade glioma patients to isolate freely circulat-
ing, cellular and exosomal microRNA signatures (Gozé et al., 2017;
Regazzo et al., 2016; Roth et al., 2011; Wang et al., 2017b). Although
all signatures showed promising results, they could not correlate to sur-
vival. More Glioma cases and their follow-up samples need to be tested
to validate the strength of our signature. However, we demonstrated
that extracellular vesicle microRNAs can realistically ﬁnd a clinical ap-
plication as diagnostic and prognostic molecular biomarkers in tumors
of glial origin.Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2018.03.022.
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